TLRs are key receptors of the innate immune system that can induce strong inflammatory responses. Our TLR modulation platform includes TLR inhibitors which control the inappropriate stimulation of TLRs that characterize many autoimmune and inflammatory diseases. These TLR inhibitors have demonstrated broad potential in multiple disease models including inflammatory skin disorders and liver fibrosis.
These first-in-class endosomal TLR inhibitors specifically target three types of immune cells; B cells, plasmacytoid dendritic cells, and neutrophils that selectively express TLR7 and TLR9. In some autoimmune diseases, for example, TLR7 and TLR9 play a key role in the overproduction of interferon alpha by plasmacytoid dendritic cells and in the generation of anti-nuclear autoantibodies by B cells.